Zacks Investment Research lowered shares of Quotient (NASDAQ:QTNT) from a hold rating to a sell rating in a research note published on Friday.
According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
A number of other analysts have also issued reports on the company. ValuEngine upgraded Quotient from a hold rating to a buy rating in a research note on Thursday, October 18th. BidaskClub upgraded Quotient from a sell rating to a hold rating in a research report on Tuesday, October 2nd.
Quotient (NASDAQ:QTNT) last released its quarterly earnings data on Monday, November 5th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $6.25 million during the quarter, compared to the consensus estimate of $5.80 million. On average, sell-side analysts predict that Quotient will post -1.92 EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of QTNT. Millennium Management LLC purchased a new position in Quotient during the second quarter worth about $3,699,000. Point72 Asset Management L.P. purchased a new position in Quotient during the second quarter worth about $3,179,000. Quantum Capital Management grew its position in Quotient by 407.7% during the third quarter. Quantum Capital Management now owns 270,961 shares of the company’s stock worth $2,046,000 after buying an additional 217,593 shares in the last quarter. Gilder Gagnon Howe & Co. LLC purchased a new position in Quotient during the second quarter worth about $1,702,000. Finally, Bellevue Group AG grew its position in Quotient by 190.7% during the second quarter. Bellevue Group AG now owns 319,814 shares of the company’s stock worth $2,568,000 after buying an additional 209,814 shares in the last quarter. Institutional investors and hedge funds own 49.19% of the company’s stock.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
See Also: Float
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.